Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
Pinkal Desai(NewYork–Presbyterian Hospital), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Srilakshmi Bathini(University of Alabama at Birmingham), Catherine Lai(University of Pennsylvania), Boaz Nachmias, Sameem Abedin(Medical College of Wisconsin), Rebecca Burne, Daniel A. Pollyea(University of Colorado Denver), Pankit Vachhani(University of Alabama at Birmingham), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Evan C. Chen(Dana-Farber Cancer Institute), Inderpreet Bhatti(Scripps MD Anderson Cancer Center), Yakir Moshe(Tel Aviv University), Neta Frankel(Roche (Israel)), Thomas W. LeBlanc(Duke University), Moshe Grunspan(Weizmann Institute of Science), Annie Guérin(Group for Research in Decision Analysis), Esprit Ma, Cat N. Bui(AbbVie (United States)), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Marin Xavier(Scripps Health), Ofir Wolach(Tel Aviv University)
Cited by 3
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Cancer-Related Fatigue, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2015|951
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Somatic mutations precede acute myeloid leukemia years before diagnosis
|Nature Medicine|2018|621